Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation
Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated AZM pharmacokinetics and pharmacokinetic-pharmacodynamic relationships in patients with cystic fibrosis (CF) and healthy subjects. Pharmacoki...
Uložené v:
| Vydané v: | Antimicrobial agents and chemotherapy Ročník 51; číslo 9; s. 3049 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.09.2007
|
| Predmet: | |
| ISSN: | 0066-4804 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated AZM pharmacokinetics and pharmacokinetic-pharmacodynamic relationships in patients with cystic fibrosis (CF) and healthy subjects. Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm. Probabilities of target attainment using percentages of time of unbound concentration above the MIC (fT>MIC) were obtained by using a Monte Carlo simulation. AZM total body clearance was significantly higher in CF patients (100.1 +/- 17.1 versus 76.2 +/- 7.4 ml/min in healthy subjects; P < 0.01). The pharmacokinetic parameter estimates for terminal half-life (1.54 +/- 0.17 h [mean +/- the standard deviation]) and volume of distribution (0.20 +/- 0.02 liters/kg in patients with CF patients were not different from those in healthy subjects. Monte Carlo simulations with a target of a fT>MIC of 50 to 60% at a dose of 1,000 mg every 8 h indicated a clinical breakpoint of 4 mg/liter and 1 to 2 mg/liter for healthy subjects and CF patients, respectively. This study using matched controls showed that AZM total body clearance and not the volume of distribution is higher in CF patients as a result of increased renal clearance. Pharmacokinetic parameter estimates in healthy subjects resulted in a clinical susceptibility breakpoint of < or =4 mg/liter for a dose of 1,000 mg every 8 h. Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly. |
|---|---|
| AbstractList | Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated AZM pharmacokinetics and pharmacokinetic-pharmacodynamic relationships in patients with cystic fibrosis (CF) and healthy subjects. Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm. Probabilities of target attainment using percentages of time of unbound concentration above the MIC (fT>MIC) were obtained by using a Monte Carlo simulation. AZM total body clearance was significantly higher in CF patients (100.1 +/- 17.1 versus 76.2 +/- 7.4 ml/min in healthy subjects; P < 0.01). The pharmacokinetic parameter estimates for terminal half-life (1.54 +/- 0.17 h [mean +/- the standard deviation]) and volume of distribution (0.20 +/- 0.02 liters/kg in patients with CF patients were not different from those in healthy subjects. Monte Carlo simulations with a target of a fT>MIC of 50 to 60% at a dose of 1,000 mg every 8 h indicated a clinical breakpoint of 4 mg/liter and 1 to 2 mg/liter for healthy subjects and CF patients, respectively. This study using matched controls showed that AZM total body clearance and not the volume of distribution is higher in CF patients as a result of increased renal clearance. Pharmacokinetic parameter estimates in healthy subjects resulted in a clinical susceptibility breakpoint of < or =4 mg/liter for a dose of 1,000 mg every 8 h. Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly. Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated AZM pharmacokinetics and pharmacokinetic-pharmacodynamic relationships in patients with cystic fibrosis (CF) and healthy subjects. Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm. Probabilities of target attainment using percentages of time of unbound concentration above the MIC (fT>MIC) were obtained by using a Monte Carlo simulation. AZM total body clearance was significantly higher in CF patients (100.1 +/- 17.1 versus 76.2 +/- 7.4 ml/min in healthy subjects; P < 0.01). The pharmacokinetic parameter estimates for terminal half-life (1.54 +/- 0.17 h [mean +/- the standard deviation]) and volume of distribution (0.20 +/- 0.02 liters/kg in patients with CF patients were not different from those in healthy subjects. Monte Carlo simulations with a target of a fT>MIC of 50 to 60% at a dose of 1,000 mg every 8 h indicated a clinical breakpoint of 4 mg/liter and 1 to 2 mg/liter for healthy subjects and CF patients, respectively. This study using matched controls showed that AZM total body clearance and not the volume of distribution is higher in CF patients as a result of increased renal clearance. Pharmacokinetic parameter estimates in healthy subjects resulted in a clinical susceptibility breakpoint of < or =4 mg/liter for a dose of 1,000 mg every 8 h. Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly.Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated AZM pharmacokinetics and pharmacokinetic-pharmacodynamic relationships in patients with cystic fibrosis (CF) and healthy subjects. Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm. Probabilities of target attainment using percentages of time of unbound concentration above the MIC (fT>MIC) were obtained by using a Monte Carlo simulation. AZM total body clearance was significantly higher in CF patients (100.1 +/- 17.1 versus 76.2 +/- 7.4 ml/min in healthy subjects; P < 0.01). The pharmacokinetic parameter estimates for terminal half-life (1.54 +/- 0.17 h [mean +/- the standard deviation]) and volume of distribution (0.20 +/- 0.02 liters/kg in patients with CF patients were not different from those in healthy subjects. Monte Carlo simulations with a target of a fT>MIC of 50 to 60% at a dose of 1,000 mg every 8 h indicated a clinical breakpoint of 4 mg/liter and 1 to 2 mg/liter for healthy subjects and CF patients, respectively. This study using matched controls showed that AZM total body clearance and not the volume of distribution is higher in CF patients as a result of increased renal clearance. Pharmacokinetic parameter estimates in healthy subjects resulted in a clinical susceptibility breakpoint of < or =4 mg/liter for a dose of 1,000 mg every 8 h. Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly. |
| Author | Vinks, Alexander A Heijerman, Harry G M Mouton, Johan W Mathôt, Ron A A van Rossem, Ronald N |
| Author_xml | – sequence: 1 givenname: Alexander A surname: Vinks fullname: Vinks, Alexander A email: sander.vinks@cchmc.org organization: Pediatric Pharmacology Research Unit, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH 45229-3039, USA. sander.vinks@cchmc.org – sequence: 2 givenname: Ronald N surname: van Rossem fullname: van Rossem, Ronald N – sequence: 3 givenname: Ron A A surname: Mathôt fullname: Mathôt, Ron A A – sequence: 4 givenname: Harry G M surname: Heijerman fullname: Heijerman, Harry G M – sequence: 5 givenname: Johan W surname: Mouton fullname: Mouton, Johan W |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17576827$$D View this record in MEDLINE/PubMed |
| BookMark | eNo10LtOxDAQBVAXIB4LHTVyRRew87CdcrXiJSFBQb-aJBNiSOzgcYDlY_hWAgvV6GrO3GIO2Y7zDhk7keJcytRcLJercyGLNE2E2mEHQiiV5Ebk--yQ6FnMuSjFHtuXutDKpPqAfT10EAao_Yt1GG1N3LccPmNA72Dg1vEOoY_dhtNUPWMdiYNr-AjRopvDu40drzc0n_LWVsGT3Qp8g36alXc_jY0nTPBj9DQF5AH73w11diQ-kXVPfPAuIq8h9J6THaatOGK7LfSEx39zwR6vLh9XN8nd_fXtanmXQCGymGgptcK6RGky1bRNAbJps8wIk2bYKFOgynWRp61A0KBzJaGsKqM0tmXWQLpgZ9vaMfjXCSmuB0s19j049BOtlZFlpoWc4ekfnKoBm_UY7ABhs_5_aPoNE5F8Fw |
| CitedBy_id | crossref_primary_10_1007_s40262_020_00932_9 crossref_primary_10_1016_j_jgar_2022_10_003 crossref_primary_10_1586_eri_09_108 crossref_primary_10_1007_s13318_020_00625_5 crossref_primary_10_1016_j_patbio_2007_08_004 crossref_primary_10_1128_AAC_00180_09 crossref_primary_10_1002_phar_2842 crossref_primary_10_1016_j_drudis_2018_11_009 crossref_primary_10_1016_j_clinthera_2011_09_010 crossref_primary_10_1002_psp4_12452 crossref_primary_10_1128_aac_00936_22 crossref_primary_10_1128_AAC_01484_10 crossref_primary_10_1128_CMR_00022_14 crossref_primary_10_1007_s40262_021_01010_4 crossref_primary_10_3389_fphar_2021_771910 crossref_primary_10_1007_s40262_020_00981_0 crossref_primary_10_1128_aac_01950_24 crossref_primary_10_1016_j_molliq_2023_123888 crossref_primary_10_1093_jac_dkq470 crossref_primary_10_1345_aph_1Q653 crossref_primary_10_1002_ppul_22655 crossref_primary_10_1002_jcph_1128 crossref_primary_10_1080_17425255_2021_1836157 crossref_primary_10_1002_jcph_810 crossref_primary_10_3390_pharmaceutics11070323 crossref_primary_10_1093_jac_dkw231 crossref_primary_10_1002_psp4_12832 crossref_primary_10_1007_s40506_018_0157_9 crossref_primary_10_1002_psp4_12159 crossref_primary_10_1128_AAC_01989_12 crossref_primary_10_1016_j_jcf_2016_04_002 crossref_primary_10_1128_AAC_00165_16 crossref_primary_10_1128_AAC_00936_09 crossref_primary_10_1128_AAC_00927_20 crossref_primary_10_1016_j_diagmicrobio_2009_06_018 crossref_primary_10_1093_jac_dkw082 crossref_primary_10_1007_s40262_018_0678_x crossref_primary_10_2146_ajhp150883 crossref_primary_10_1016_j_pedhc_2015_07_010 crossref_primary_10_1128_AAC_01066_18 crossref_primary_10_3390_pharmaceutics11060286 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1128/AAC.01522-06 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 17576827 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: U10 HD037249 |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ 7X8 AAGFI |
| ID | FETCH-LOGICAL-a503t-71176ec9e1836dfd5a1df3380823ed685e647542f0ea7a7461a9bb867ef93da2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 47 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000249175400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0066-4804 |
| IngestDate | Thu Sep 04 15:19:41 EDT 2025 Sat Sep 28 07:48:36 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a503t-71176ec9e1836dfd5a1df3380823ed685e647542f0ea7a7461a9bb867ef93da2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/2043218 |
| PMID | 17576827 |
| PQID | 68193701 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_68193701 pubmed_primary_17576827 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-09-01 |
| PublicationDateYYYYMMDD | 2007-09-01 |
| PublicationDate_xml | – month: 09 year: 2007 text: 2007-09-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2007 |
| References | 3881946 - Am J Med. 1985 Feb 8;78(2A):11-8 7272167 - Br J Clin Pharmacol. 1981 May;11(5):523-6 14614372 - Pediatr Infect Dis J. 2003 Nov;22(11):982-92; quiz 993-5 10817724 - Antimicrob Agents Chemother. 2000 Jun;44(6):1655-9 11109013 - Diagn Microbiol Infect Dis. 2000 Nov;38(3):151-7 3774385 - Pediatr Pulmonol. 1986 Sep-Oct;2(5):282-6 15964500 - Diagn Microbiol Infect Dis. 2005 Jun;52(2):123-7 2106410 - Chest. 1990 Mar;97(3):611-7 16506354 - Pharmacotherapy. 2006 Jan;26(1):129-34 14711073 - Infect Dis Clin North Am. 2003 Sep;17(3):479-501 9455502 - Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 3588112 - Pediatr Infect Dis J. 1987 Apr;6(4):393-7 9249216 - J Antimicrob Chemother. 1997 Jul;40(1):125-33 11558860 - Clin Ther. 2001 Aug;23(8):1231-44 3311531 - Clin Pharmacokinet. 1987 Oct;13(4):228-53 671222 - J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75 14711078 - Infect Dis Clin North Am. 2003 Sep;17(3):579-98 8739261 - Pharm World Sci. 1996 Apr;18(2):74-7 11120938 - Antimicrob Agents Chemother. 2001 Jan;45(1):13-22 3319914 - Infection. 1987;15(5):385-96 1884324 - Clin Rev Allergy. 1991 Spring-Summer;9(1-2):169-210 3286083 - Clin Pharmacokinet. 1988 Mar;14(3):148-55 16117983 - Clin Ther. 2005 Jun;27(6):762-72 11236807 - Clin Pharmacokinet. 2001 Jan;40(1):15-22 3128767 - Pediatr Infect Dis J. 1988 Mar;7(3):171-6 3558660 - J Chromatogr. 1987 Jan 23;413:109-19 16807729 - Eur J Pediatr. 2006 Dec;165(12):819-29 15105125 - Antimicrob Agents Chemother. 2004 May;48(5):1713-8 1641599 - Scand J Infect Dis. 1992;24(2):215-8 16584284 - Clin Pharmacokinet. 2006;45(4):365-83 3909322 - Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S669-74 9812180 - Clin Pharmacokinet. 1998 Oct;35(4):313-29 8162661 - Clin Pharmacokinet. 1994 Feb;26(2):99-106 8885120 - Ther Drug Monit. 1996 Oct;18(5):562-9 7199041 - J Antimicrob Chemother. 1981 Dec;8 Suppl E:131-40 11709326 - Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73 10850402 - Ther Drug Monit. 2000 Jun;22(3):325-9 |
| References_xml | – reference: 14711073 - Infect Dis Clin North Am. 2003 Sep;17(3):479-501 – reference: 15964500 - Diagn Microbiol Infect Dis. 2005 Jun;52(2):123-7 – reference: 3286083 - Clin Pharmacokinet. 1988 Mar;14(3):148-55 – reference: 3319914 - Infection. 1987;15(5):385-96 – reference: 7199041 - J Antimicrob Chemother. 1981 Dec;8 Suppl E:131-40 – reference: 9455502 - Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 – reference: 1884324 - Clin Rev Allergy. 1991 Spring-Summer;9(1-2):169-210 – reference: 11236807 - Clin Pharmacokinet. 2001 Jan;40(1):15-22 – reference: 3588112 - Pediatr Infect Dis J. 1987 Apr;6(4):393-7 – reference: 10850402 - Ther Drug Monit. 2000 Jun;22(3):325-9 – reference: 14711078 - Infect Dis Clin North Am. 2003 Sep;17(3):579-98 – reference: 2106410 - Chest. 1990 Mar;97(3):611-7 – reference: 16584284 - Clin Pharmacokinet. 2006;45(4):365-83 – reference: 16117983 - Clin Ther. 2005 Jun;27(6):762-72 – reference: 10817724 - Antimicrob Agents Chemother. 2000 Jun;44(6):1655-9 – reference: 3311531 - Clin Pharmacokinet. 1987 Oct;13(4):228-53 – reference: 9249216 - J Antimicrob Chemother. 1997 Jul;40(1):125-33 – reference: 11120938 - Antimicrob Agents Chemother. 2001 Jan;45(1):13-22 – reference: 14614372 - Pediatr Infect Dis J. 2003 Nov;22(11):982-92; quiz 993-5 – reference: 1641599 - Scand J Infect Dis. 1992;24(2):215-8 – reference: 16506354 - Pharmacotherapy. 2006 Jan;26(1):129-34 – reference: 8162661 - Clin Pharmacokinet. 1994 Feb;26(2):99-106 – reference: 11558860 - Clin Ther. 2001 Aug;23(8):1231-44 – reference: 15105125 - Antimicrob Agents Chemother. 2004 May;48(5):1713-8 – reference: 7272167 - Br J Clin Pharmacol. 1981 May;11(5):523-6 – reference: 3881946 - Am J Med. 1985 Feb 8;78(2A):11-8 – reference: 3774385 - Pediatr Pulmonol. 1986 Sep-Oct;2(5):282-6 – reference: 8739261 - Pharm World Sci. 1996 Apr;18(2):74-7 – reference: 16807729 - Eur J Pediatr. 2006 Dec;165(12):819-29 – reference: 9812180 - Clin Pharmacokinet. 1998 Oct;35(4):313-29 – reference: 671222 - J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75 – reference: 8885120 - Ther Drug Monit. 1996 Oct;18(5):562-9 – reference: 3558660 - J Chromatogr. 1987 Jan 23;413:109-19 – reference: 3909322 - Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S669-74 – reference: 3128767 - Pediatr Infect Dis J. 1988 Mar;7(3):171-6 – reference: 11109013 - Diagn Microbiol Infect Dis. 2000 Nov;38(3):151-7 – reference: 11709326 - Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73 |
| SSID | ssj0006590 |
| Score | 2.1069324 |
| Snippet | Aztreonam (AZM) is a monobactam antibiotic with a high level of activity against gram-negative micro-organisms, including Pseudomonas aeruginosa. We evaluated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3049 |
| SubjectTerms | Adult Algorithms Anti-Bacterial Agents - cerebrospinal fluid Anti-Bacterial Agents - pharmacokinetics Aztreonam - cerebrospinal fluid Aztreonam - pharmacokinetics Cystic Fibrosis - metabolism Dose-Response Relationship, Drug Female Half-Life Humans Male Models, Statistical Monte Carlo Method |
| Title | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17576827 https://www.proquest.com/docview/68193701 |
| Volume | 51 |
| WOSCitedRecordID | wos000249175400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB4VChUXHqGF8pwD6qmmfu5DQkJRRcWBRjlEKLdovQ9qQeyQTVHdH8NvZTa2lRPiwMWSpV1r5Zmd93wD8E5qy5wUSZSmnBwUQTe95KWLrFDaMG0Tve1y_fqFTyZiPpfTPfgw9MKEsspBJm4FtWl0iJGfMVJdGY-Tj6ufUZgZFXKr_QCNO7CfkSETriWf77DCWdFFWEip0iHifCh7T8XZeHz-nvQg-WEx-7tpuVUxF4_-73CP4WFvWuK444UnsGfrEdzvhk22Izi47NPoIziZdoDV7SnOdv1X_hRPcLqDsm6fwu_h9TvtC0uwcahuN2tLBvwSqxq7PsoW_XUZIjoeVW2wB2v1GKK8qNuABY2OHPPGV92KHch4-KJpvI3szaoJ4UpcD_V5V9XKYyjM_4bLAKKFWq1_NOirZT9z7BBmF59m55-jfqJDpIo420Q8STizWloSJMw4U6jEOHKSQ7rPGiYKy_IwktfFVnHFc5YoWZaCcetkZlR6BHfrprbPAel3ayWLQomszHNZity4UiZaxFIQg6XH8Hag1IIuTMiCqNo2134x0OoYnnXEXqw6XI8FWVLkfKX8xT_3voQHXYw31Jq9gn1HosK-hnv616by6zdbPqTnZHr5B20i7O4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+aztreonam+in+healthy+subjects+and+patients+with+cystic+fibrosis+and+evaluation+of+dose-exposure+relationships+using+monte+carlo+simulation&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Vinks%2C+Alexander+A&rft.au=van+Rossem%2C+Ronald+N&rft.au=Math%C3%B4t%2C+Ron+A+A&rft.au=Heijerman%2C+Harry+G+M&rft.date=2007-09-01&rft.issn=0066-4804&rft.volume=51&rft.issue=9&rft.spage=3049&rft_id=info:doi/10.1128%2FAAC.01522-06&rft_id=info%3Apmid%2F17576827&rft_id=info%3Apmid%2F17576827&rft.externalDocID=17576827 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |